Lurbinectedin/Lurbinectedin’s domestic launch time and approval information

Lurbinectedin (Lurbinectedin) is a new type of anti-tumor drug, which is a DNA binding alkylating agent. It binds to the DNA double helix and interferes with the transcription process, inducing the apoptosis of cancer cells, thereby exerting anti-tumor effects. It has shown good clinical efficacy in small cell lung cancer and some solid tumors, so it has become one of the important drugs in the field of lung cancer treatment in recent years. As an innovative drug, rubicatin has received widespread attention during the development and approval process, and its clinical trial data has provided important basis for domestic and foreign regulatory agencies.

In terms of the domestic approval process, Rubicatin has completed clinical trials and officially obtained drug registration permission, enabling the original drug to be launched in the country. Although it is currently on the market, its pricing has not yet been fully disclosed because it has just entered the domestic market. Patients can learn the latest purchase price through the hospital pharmacy or official channels. The domestic launch marks that patients can obtain this innovative drug locally, providing a new treatment option for patients with small cell lung cancer and other indications.

In terms of price, the specific selling price of Ruby Cardin in the domestic market is still uncertain, but you can refer to the situation in overseas markets. The original version sold in Hong Kong, 4mg, is priced at about 2 more than 2 per box, and the price may fluctuate due to exchange rates. In addition, the price of the US version of the original drug is as high as more than 90,000 yuan, while the Singapore version is about more than 30,000 yuan, showing obvious price differences in the international market. Since there are currently no generic drugs of Rubicatin available overseas, the price is still dominated by the original drug, and the economic cost is relatively high.

Overall, the domestic launch of rubicatin provides new treatment opportunities for patients, especially for high-risk patients with small cell lung cancer and other high-risk patients. Although the specific price information has not yet been fully disclosed, it can be purchased through formal channels and must be used under the guidance of a doctor. With market promotion and the accumulation of more clinical experience, it is expected that there will be further improvements in price, indications and medication specifications in the future, bringing safer and more effective treatment options to patients.

Reference materials:https://www.drugs.com/